Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Price, News & Analysis

Lumos Pharma logo

About Lumos Pharma Stock (NASDAQ:LUMO)

Advanced Chart

Key Stats

Today's Range
$4.34
$4.34
50-Day Range
$4.30
$4.41
52-Week Range
$1.37
$4.58
Volume
N/A
Average Volume
79,835 shs
Market Capitalization
$37.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.63
Consensus Rating
Buy

Company Overview

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

LUMO Stock News Headlines

Lumos Pharma Completes Merger and Delisting Process
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
Lumos Pharma reports sustained growth in PGHD trials
See More Headlines

LUMO Stock Analysis - Frequently Asked Questions

Lumos Pharma, Inc. (NASDAQ:LUMO) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.34. The company had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.50 million. Lumos Pharma had a negative trailing twelve-month return on equity of 233.03% and a negative net margin of 1,583.49%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE).

Company Calendar

Last Earnings
11/07/2024
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LUMO
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.63
High Stock Price Target
$13.00
Low Stock Price Target
$4.25
Potential Upside/Downside
+98.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.03 million
Net Margins
-1,583.49%
Pretax Margin
-1,583.49%

Debt

Sales & Book Value

Annual Sales
$2.21 million
Price / Cash Flow
N/A
Book Value
$3.45 per share
Price / Book
1.26

Miscellaneous

Free Float
6,452,000
Market Cap
$37.54 million
Optionable
Not Optionable
Beta
0.74
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:LUMO) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners